RE:RE:RE:RE:RE:Thyroid cancerWe will find out, and it is a very dynamic sector simply because the ability to change the life, even if just for a minor proportion of patients and for a limited time frame, is essentially a priceless trade and thus very valuable commercially.
I think one very clear thing for us to keep in mind, when I see all these other ADC and various other cancer approach results, the SAEs are usually quite severe. Some even have deaths in the trial. The potential for delivering a chemo that is well above the normal dose because of the accurate endocytosis via sortilin and the ability for it not to get spit back out by the MDR efflux resistance pump is really very valuable for us. Safety is that much more --- I mean multiples better --- than what I see in these other trials. The other trials usually have around 20-25% of the population that gets more serious SAEs than what we've seen --SAEs that knock them out of the trial. Most have at least a death or two, which we hope not to see any.
The ability to then throttle dosage and schedule is another aspect TH1902 may just have versus anything else out there right now. So I don't think it's a PR stunt for Levesque/Bellevieu/Marsolais to say they are a first-mover in a potentially "game-changing" approach via a PDC targeting Sortilin. They just need to show us all some efficacy on a wider and deeper patient pool.
Just so you can see what I'm talking about, here's the numbers for all the metastatic NC Prostate tumor trials going on from that Daiichi trial I mentioned earlier today. These are the competitor numbers (Daiichi hasn't released anything beyond that ORR). The other therapies are from Exelixis, MacroGenics, Arcus, Novartis, Merck, Sanofi (they don't all have all these numbers reported).
Grade >=3 TRAEs% 56% (74/132), 50% (43/86), 35% (6/17), 28% (150/529), 40% (42/104), 18% (68/378)
Discontinuation due to AEs: 21%, 7%, 12%, 18%
Deaths due to TRAEs: 1%, 1%, 0%, 1%, 0%, 2%
Really shows you that if we can establish a super safe profile (hopefully), solid response rates and clear efficacy, it will be a game-changer in my opinion.
Lee430 wrote: Seems like most news feed I get these dasys has some new promising breakthrough cancer therapy article almost every day, It does make me question whether I am as Wino said “the genius or the chump here”